17 мая 2021 г. · In summary, in the RESCUE trial, the novel IL-6 ligand monoclonal antibody ziltivekimab was highly effective at reducing multiple inflammatory ... |
29 мая 2021 г. · Methods: RESCUE is a randomised, double-blind, phase 2 trial done at 40 clinical sites in the USA. Inclusion criteria were age 18 years or older ... |
19 мая 2023 г. · Here, we report the efficacy and safety of ziltivekimab in Japanese patients. Methods: RESCUE-2 was a randomized, double-blind, 12-week, phase 2 ... |
In the phase 2 trial RESCUE, ziltivekimab significantly reduced biomarkers of inflammation, including hsCRP, compared with placebo in patients at high ... |
29 мая 2023 г. · In the phase 2 trial RESCUE, ziltivekimab significantly reduced biomarkers of inflammation, including hsCRP, compared with placebo in ... |
22 окт. 2024 г. · The phase-2 RESCUE trial initially supported the ziltivekimab's efficacy in reducing inflammatory biomarkers, including CRP, among patients ... |
30 нояб. 2022 г. · Results of this post hoc analysis of the RESCUE trial show that IL-6 ligand inhibition with ziltivekimab associates with a lower NLR. |
In the randomized, double-blind, placebo-controlled phase 2 trial RESCUE (NCT03926117), ziltivekimab dose-dependently reduced the biomarkers of inflammation ... |
The magnitude of change with ziltivekimab on hsCRP was nearly twice as large in. RESCUE as that observed in the CANTOS trial of canakinumab where cardiovascular ... |
| Novbeti > |
| Axtarisha Qayit Anarim.Az Anarim.Az Sayt Rehberliyi ile Elaqe Saytdan Istifade Qaydalari Anarim.Az 2004-2023 |